Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Anti-hCD3 antibodies
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abzyme Files Patent Application for pH-Dependent Anti-CD3 Antibodies
Details : This patent application is an important step forward for Abzyme Therapeutics solidifying its intellectual property position in the field of therapeutic antibody development.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 16, 2020
Lead Product(s) : Anti-hCD3 antibodies
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?